Diabetes-induced changes in mannan-binding lectin levels and complement activation in a mouse model of type 1 diabetes

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avisTidsskriftartikelForskningpeer review

Standard

Diabetes-induced changes in mannan-binding lectin levels and complement activation in a mouse model of type 1 diabetes. / Østergaard, Jakob; Bjerre, Mette; Dagnaes-Hansen, Frederik; Hansen, Troels Krarup; Thiel, Steffen; Flyvbjerg, Allan.

I: Scandinavian Journal of Immunology, Bind 77, Nr. 3, 2013, s. 187-94.

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avisTidsskriftartikelForskningpeer review

Harvard

APA

CBE

MLA

Vancouver

Author

Bibtex

@article{faaa86153bda408ea96073b7fba05d59,
title = "Diabetes-induced changes in mannan-binding lectin levels and complement activation in a mouse model of type 1 diabetes",
abstract = "Circulating mannan-binding lectin (MBL) levels are elevated in type 1 diabetes. Further, high MBL levels are associated with the development of diabetic nephropathy. In animals, a direct effect of MBL on diabetic kidney changes is observed. We hypothesized that MBL levels and detrimental complement activation increase as a consequence of diabetes. We measured plasma MBL before and seven weeks after inducing diabetes by streptozotocin. Mice have two MBLs, MBL-A and MBL-C. Diabetes-induction led to an increase in MBL-C concentration whereas no change during the study was found in the control group. The increase in MBL-C was associated with the increasing plasma glucose levels. In accordance with the observed changes in circulating MBL levels, liver expression of Mbl2 mRNA (encoding MBL-C) was increased in diabetes. Mbl1 expression (encoding MBL-A) did not differ between diabetic and control animals. The estimated half-life of recombinant human MBL was significantly prolonged in mice with diabetes compared with control mice. Complement activation in plasma and glomeruli did not differ between groups. We demonstrate for the first time that MBL levels increase after induction of diabetes and in parallel with increasing plasma glucose. Our findings support the previous clinical observations of increased MBL in type 1 diabetes. This change may be explained by alternations both in MBL production and turnover.",
author = "Jakob {\O}stergaard and Mette Bjerre and Frederik Dagnaes-Hansen and Hansen, {Troels Krarup} and Steffen Thiel and Allan Flyvbjerg",
note = "{\textcopyright} 2013 The Authors. Scandinavian Journal of Immunology {\textcopyright} 2013 Blackwell Publishing Ltd.",
year = "2013",
doi = "10.1111/sji.12027",
language = "English",
volume = "77",
pages = "187--94",
journal = "Scandinavian Journal of Immunology",
issn = "0300-9475",
publisher = "Wiley-Blackwell Publishing Ltd.",
number = "3",

}

RIS

TY - JOUR

T1 - Diabetes-induced changes in mannan-binding lectin levels and complement activation in a mouse model of type 1 diabetes

AU - Østergaard, Jakob

AU - Bjerre, Mette

AU - Dagnaes-Hansen, Frederik

AU - Hansen, Troels Krarup

AU - Thiel, Steffen

AU - Flyvbjerg, Allan

N1 - © 2013 The Authors. Scandinavian Journal of Immunology © 2013 Blackwell Publishing Ltd.

PY - 2013

Y1 - 2013

N2 - Circulating mannan-binding lectin (MBL) levels are elevated in type 1 diabetes. Further, high MBL levels are associated with the development of diabetic nephropathy. In animals, a direct effect of MBL on diabetic kidney changes is observed. We hypothesized that MBL levels and detrimental complement activation increase as a consequence of diabetes. We measured plasma MBL before and seven weeks after inducing diabetes by streptozotocin. Mice have two MBLs, MBL-A and MBL-C. Diabetes-induction led to an increase in MBL-C concentration whereas no change during the study was found in the control group. The increase in MBL-C was associated with the increasing plasma glucose levels. In accordance with the observed changes in circulating MBL levels, liver expression of Mbl2 mRNA (encoding MBL-C) was increased in diabetes. Mbl1 expression (encoding MBL-A) did not differ between diabetic and control animals. The estimated half-life of recombinant human MBL was significantly prolonged in mice with diabetes compared with control mice. Complement activation in plasma and glomeruli did not differ between groups. We demonstrate for the first time that MBL levels increase after induction of diabetes and in parallel with increasing plasma glucose. Our findings support the previous clinical observations of increased MBL in type 1 diabetes. This change may be explained by alternations both in MBL production and turnover.

AB - Circulating mannan-binding lectin (MBL) levels are elevated in type 1 diabetes. Further, high MBL levels are associated with the development of diabetic nephropathy. In animals, a direct effect of MBL on diabetic kidney changes is observed. We hypothesized that MBL levels and detrimental complement activation increase as a consequence of diabetes. We measured plasma MBL before and seven weeks after inducing diabetes by streptozotocin. Mice have two MBLs, MBL-A and MBL-C. Diabetes-induction led to an increase in MBL-C concentration whereas no change during the study was found in the control group. The increase in MBL-C was associated with the increasing plasma glucose levels. In accordance with the observed changes in circulating MBL levels, liver expression of Mbl2 mRNA (encoding MBL-C) was increased in diabetes. Mbl1 expression (encoding MBL-A) did not differ between diabetic and control animals. The estimated half-life of recombinant human MBL was significantly prolonged in mice with diabetes compared with control mice. Complement activation in plasma and glomeruli did not differ between groups. We demonstrate for the first time that MBL levels increase after induction of diabetes and in parallel with increasing plasma glucose. Our findings support the previous clinical observations of increased MBL in type 1 diabetes. This change may be explained by alternations both in MBL production and turnover.

U2 - 10.1111/sji.12027

DO - 10.1111/sji.12027

M3 - Journal article

C2 - 23350935

VL - 77

SP - 187

EP - 194

JO - Scandinavian Journal of Immunology

JF - Scandinavian Journal of Immunology

SN - 0300-9475

IS - 3

ER -